Overview
Osteoporosis, with current studies that focus on advances in diagnosis and natural history of male and postmenopausal osteoporosis. The study on male osteoporosis include a collaborative study with outside investigators is examining the utility of lateral spine bone densitometry in identifying men with osteoporosis and low trauma fractures.
Hypophosphatemic disorders, including X-link hypophosphatemic rickets and tumor-induced osteomalacia. My ongoing research study, in collaboration with Dr. L Darryl Quarles at the University of Kansas, seeks to further confirm and extend our understanding of the role of FGF-23 in human disorders of phosphate homeostasis, including patients with chronic kidney disease. Pending studies include primary and sub-investigator directed Phase 1 / 2 first in human studies examining the effects of a monoclonal antibody and enzyme replacement therapy for X-linked hypophosphatemic rickets and hypophosphatasia, respectively.
Hypophosphatemic disorders, including X-link hypophosphatemic rickets and tumor-induced osteomalacia. My ongoing research study, in collaboration with Dr. L Darryl Quarles at the University of Kansas, seeks to further confirm and extend our understanding of the role of FGF-23 in human disorders of phosphate homeostasis, including patients with chronic kidney disease. Pending studies include primary and sub-investigator directed Phase 1 / 2 first in human studies examining the effects of a monoclonal antibody and enzyme replacement therapy for X-linked hypophosphatemic rickets and hypophosphatasia, respectively.
Current Appointments & Affiliations
Professor of Medicine
·
2021 - Present
Medicine, Endocrinology, Metabolism, and Nutrition,
Medicine
Member of the Duke Cancer Institute
·
2016 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Pharmacodynamic Exposure-Response Analysis of Fracture Count Data Following Treatment with Burosumab in Patients with XLH.
Journal Article Journal of clinical pharmacology · February 2025 X-linked hypophosphatemia (XLH) is a rare genetic disorder caused by excessive fibroblast growth factor 23 (FGF23), leading to low serum phosphate levels resulting in increased risk of fractures and pseudofractures. Burosumab is indicated for the treatment ... Full text CiteLong-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia.
Journal Article J Clin Endocrinol Metab · December 17, 2022 CONTEXT: Burosumab was developed as a treatment option for patients with the rare, lifelong, chronically debilitating, genetic bone disease X-linked hypophosphatemia (XLH). OBJECTIVE: Collect additional information on the safety, immunogenicity, and clinic ... Full text Link to item CitePerception of clinical research among patients and healthy volunteers of clinical trials.
Journal Article Eur J Clin Pharmacol · October 2022 PURPOSE: Clinical research relies on data from patients and volunteers, yet the target sample size is often not achieved. Here, we assessed the perception of clinical research among clinical trial participants to improve the recruitment process for future ... Full text Link to item CiteRecent Grants
Endocrinology and Metabolism Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2024 - 2029X-linked Hypophosphatemia Disease Monitoring Program (XLH-DMP) UX023-CL401
ResearchPrincipal Investigator · Awarded by Ultragenyx Pharmaceutical · 2018 - 2028Characterizing neurocognitive symptoms in older adults with primary hyperparathyroidism
ResearchCollaborator · Awarded by National Institutes of Health · 2023 - 2025View All Grants
Education, Training & Certifications
The University of Chicago ·
1989
M.D.